Literature DB >> 26581344

What is damaging the kidney in lupus nephritis?

Anne Davidson1.   

Abstract

Despite marked improvements in the survival of patients with severe lupus nephritis over the past 50 years, the rate of complete clinical remission after immune suppression therapy is <50% and renal impairment still occurs in 40% of affected patients. An appreciation of the factors that lead to the development of chronic kidney disease following acute or subacute renal injury in patients with systemic lupus erythematosus is beginning to emerge. Processes that contribute to end-stage renal injury include continuing inflammation, activation of intrinsic renal cells, cell stress and hypoxia, metabolic abnormalities, aberrant tissue repair and tissue fibrosis. A deeper understanding of these processes is leading to the development of novel or adjunctive therapies that could protect the kidney from the secondary non-immune consequences of acute injury. Approaches based on a molecular-proteomic-lipidomic classification of disease should yield new information about the functional basis of disease heterogeneity so that the most effective and least toxic treatment regimens can be formulated for individual patients.

Entities:  

Mesh:

Year:  2015        PMID: 26581344      PMCID: PMC4820834          DOI: 10.1038/nrrheum.2015.159

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  164 in total

1.  Learning in motion: pericytes instruct migrating innate leukocytes.

Authors:  Ronen Alon; Sussan Nourshargh
Journal:  Nat Immunol       Date:  2013-01       Impact factor: 25.606

Review 2.  Crosstalk between fibroblasts and inflammatory cells.

Authors:  Sophie Van Linthout; Kapka Miteva; Carsten Tschöpe
Journal:  Cardiovasc Res       Date:  2014-04-11       Impact factor: 10.787

3.  Factors associated with poor outcomes in patients with lupus nephritis.

Authors:  G Contreras; V Pardo; C Cely; E Borja; A Hurtado; C De La Cuesta; K Iqbal; O Lenz; A Asif; N Nahar; B Leclerq; C Leon; I Schulman; F Ramirez-Seijas; A Paredes; A Cepero; T Khan; F Pachon; E Tozman; G Barreto; D Hoffman; M Almeida Suarez; J C Busse; M Esquenazi; A Esquenazi; L Garcia Mayol; H Garcia Estrada
Journal:  Lupus       Date:  2005       Impact factor: 2.911

4.  Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus.

Authors:  Anirudh J Ullal; Charles F Reich; Megan Clowse; Lisa G Criscione-Schreiber; Martin Tochacek; Marc Monestier; David S Pisetsky
Journal:  J Autoimmun       Date:  2011-03-03       Impact factor: 7.094

5.  Inhibition of type I interferon signalling prevents TLR ligand-mediated proteinuria.

Authors:  Sevgi Gurkan; Allison Cabinian; Victoria Lopez; Mantu Bhaumik; Jer-Ming Chang; Arnold B Rabson; Peter Mundel
Journal:  J Pathol       Date:  2013-10       Impact factor: 7.996

6.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

Review 7.  Epigenetic regulation in the acute kidney injury to chronic kidney disease transition.

Authors:  Roxana Rodríguez-Romo; Nathan Berman; Arturo Gómez; Norma A Bobadilla
Journal:  Nephrology (Carlton)       Date:  2015-10       Impact factor: 2.506

8.  Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations.

Authors:  Shuei Liong Lin; Ana P Castaño; Brian T Nowlin; Mark L Lupher; Jeremy S Duffield
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

9.  Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites.

Authors:  D V Vlahakos; M H Foster; S Adams; M Katz; A A Ucci; K J Barrett; S K Datta; M P Madaio
Journal:  Kidney Int       Date:  1992-06       Impact factor: 10.612

10.  Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.

Authors:  Farah Tamirou; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Christoph Fiehn; Maria del Mar Ayala Guttierez; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera; Frédéric A Houssiau
Journal:  Ann Rheum Dis       Date:  2015-03-10       Impact factor: 19.103

View more
  90 in total

1.  Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study.

Authors:  Anna Broder; Wenzhu B Mowrey; Hina N Khan; Bojana Jovanovic; Alejandra Londono-Jimenez; Peter Izmirly; Chaim Putterman
Journal:  Semin Arthritis Rheum       Date:  2017-07-14       Impact factor: 5.532

Review 2.  Immune Cell Metabolism in Systemic Lupus Erythematosus.

Authors:  Seung-Chul Choi; Anton A Titov; Ramya Sivakumar; Wei Li; Laurence Morel
Journal:  Curr Rheumatol Rep       Date:  2016-11       Impact factor: 4.592

3.  Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted.

Authors:  Jeremy S Tilstra; Lyndsay Avery; Ashley V Menk; Rachael A Gordon; Shuchi Smita; Lawrence P Kane; Maria Chikina; Greg M Delgoffe; Mark J Shlomchik
Journal:  J Clin Invest       Date:  2018-09-24       Impact factor: 14.808

4.  Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults.

Authors:  Hermine I Brunner; Michael R Bennett; Gaurav Gulati; Khalid Abulaban; Marisa S Klein-Gitelman; Stacy P Ardoin; Lori B Tucker; Kelly A Rouster-Stevens; David Witte; Jun Ying; Prasad Devarajan
Journal:  J Rheumatol       Date:  2017-06-15       Impact factor: 4.666

Review 5.  Metabolic Factors that Contribute to Lupus Pathogenesis.

Authors:  Wei Li; Ramya Sivakumar; Anton A Titov; Seung-Chul Choi; Laurence Morel
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

6.  iRhom2 promotes lupus nephritis through TNF-α and EGFR signaling.

Authors:  Xiaoping Qing; Yurii Chinenov; Patricia Redecha; Michael Madaio; Joris Jth Roelofs; Gregory Farber; Priya D Issuree; Laura Donlin; David R Mcllwain; Tak W Mak; Carl P Blobel; Jane E Salmon
Journal:  J Clin Invest       Date:  2018-03-05       Impact factor: 14.808

Review 7.  Metabolic determinants of lupus pathogenesis.

Authors:  Xiangyu Teng; Josephine Brown; Seung-Chul Choi; Wei Li; Laurence Morel
Journal:  Immunol Rev       Date:  2020-03-12       Impact factor: 12.988

8.  The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.

Authors:  Jonathan Sitrin; Eric Suto; Arthur Wuster; Jeffrey Eastham-Anderson; Jeong M Kim; Cary D Austin; Wyne P Lee; Timothy W Behrens
Journal:  J Immunol       Date:  2017-07-10       Impact factor: 5.422

Review 9.  T cells and autoimmune kidney disease.

Authors:  Abel Suárez-Fueyo; Sean J Bradley; David Klatzmann; George C Tsokos
Journal:  Nat Rev Nephrol       Date:  2017-03-13       Impact factor: 28.314

10.  Opposing Roles of Tyrosine Kinase Receptors Mer and Axl Determine Clinical Outcomes in Experimental Immune-Mediated Nephritis.

Authors:  Yuxuan Zhen; Stephen O Priest; Wen-Hai Shao
Journal:  J Immunol       Date:  2016-08-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.